Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?
Anthonie W. A. Lensing (1) , Martin H. Prins (2)
From the (1) Centre for Vascular Medicine, and the (2) Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, The Netherlands
In the past decades considerable progress has been made in the
understanding of inherited and acquired causes of venous thrombosis
and their clinical impact (1). Thus, the risk of a first venous thrombosis
is approximately 10-fold increased in subjects with deficiency of antithrombin,
protein C or S (1, 2), 7-fold increased in patients with
cancer (3), or the antiphospholipid antibody syndrome (4, 5), and 3 to
5-fold in carriers of the G1691A allele in the coagulation factor V gene
and the G20210A allele in the prothrombin gene (6-8). All together,
these conditions can be identified in more than 50% of patients with a
first episode of venous thrombosis (1, 2, 8).